<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01606163</url>
  </required_header>
  <id_info>
    <org_study_id>GC1102</org_study_id>
    <nct_id>NCT01606163</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics Study of Healthy Male Adults When Repeatedly Administered Through Intravenous Injection</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Placebo-controlled, Multiple-dose, Dose Escalation Study to Assess the Safety and Pharmacokinetics of GC1102 (Hepabig-Gene) in Healthy Male Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Green Cross Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Green Cross Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and pharmacokinetics of healthy male
      adults when subjects are repeatedly administered GC1102 (Hepabig_Gene) through intravenous
      injection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of GC1102 when repeatedly administered by intravenous injection to healthy male adults</measure>
    <time_frame>screening, -1d, 1d, 2d, 3d, 4d, 5d, 6d, 7d, 8d, 9d, 14d, 21d, 28d</time_frame>
    <description>Adverse event
Diagnostic examinations
Physical examinations
Vital signs
ECG(electrocardiogram)
Check of concomitant drug</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of GC1102 when repeatedly administered by intravenous injection to healthy male adults</measure>
    <time_frame>1)1d:predose(0h), 0.5, 1, 2, 5, 9, 14 hours after dose 2) 2d~6d:predose(0h) 3) 7d:predose(0h), 0.5, 1, 2, 5, 9, 14 hours after dose 4) 8d, 9d, 14d, 21d, 28d: 0h</time_frame>
    <description>Terminal elimination half-life (t½β)
Maximum and Average concentration at steady state(Cmax,ss, Cav,ss,)
Area-under the concentration-time curve within a dosing interval at steady state (AUCτ,ss)
Clearance (CL)
Volume of distribution at steady state (Vd,ss)
Mean residence time (MRT)
Accumulation Index (AI)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug:GC1102
Amount:3ml (30,000IU)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: GC1102
Amount: 5ml(50,000IU)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: GC1102
Amount: 8ml (80,000IU)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>drug: JW normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GC1102</intervention_name>
    <description>Description: GC1102 IV bolus injection during 10~ 30 seconds.
Amount: group1-3ml, group2-5ml, group3-8ml
Subject number: group1-8, group2-8, group3-8
Administration time: 1day, 2day, 3day, 4day, 5day, 6day, 7day(total: 7 times)</description>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_label>group 2</arm_group_label>
    <arm_group_label>group 3</arm_group_label>
    <other_name>Hepabig_Gene</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>JW normal saline</intervention_name>
    <description>Description: Normal saline IV bolus injection through 10~ 30 seconds.
Each 3 subjects of this placebo comparator group will match with group 1,2,3 respectively. Placebo comparator subjects in each group will be treated with same condition of each group(group 1, group 2, group 3) except being administered JW normal saline.
Subject number: 9
Administration time: 1day, 2day, 3day, 4day, 5day, 6day, 7day(total: 7 times)</description>
    <arm_group_label>group 4</arm_group_label>
    <other_name>saline solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Those who are healthy, male adult aged 20 years- 45 years when screened.

          -  Those whose body weights are over 45kg when screened, and whose BMI scores are
             19kg/㎡-28 kg/㎡.

          -  Those whose HBs-Ag, HBc-Ab(IgM), HBc-Ab(IgG), HBV DNA quantitative are all negative
             when screened.

          -  Those whose HBs-Ab(titer) in blood is below 500 IU/L when screened.

          -  Those who agree to use double protective contraceptive measures from one days before
             administration of first investigative drug to last follow-up visit(protective
             contraceptive measures using more than 2 ways among a male condom, a female condom of
             sex partner, a spermicide of sex partner, an intrauterine device(IUD) of sex partner,
             a diaphragm of sex partner and a cervical cap of sex partner), and not to provide
             sperm.

          -  Those who voluntarily decide to follow matters that require attention of this study
             and give written consent to participate in this clinical trial.

          -  Those who can visit the medical center to be monitored, and agree to collect blood
             during study period.

        Exclusion Criteria:

          -  Those who have GC1102 anti-body when screened

          -  Those who have a clinically meaningful disease or history concerning liver, kidney,
             alimentary system, respiratory system, musculoskeletal system, endocrine system,
             neuropsychiatry system, blood tumor system, cardiovascular system.

          -  Those who have anaphylaxis of drug allergy including HBIG or who have allergy disease
             requiring treatment.

          -  Those who have immunodeficiency disease now.

          -  Those who have an anamnesis of Guillain-Barre syndrome.

          -  Hemophiliac patients who have a risk of serious bleeding when getting a shot through
             intravascular injection or those who are being administered anticoagulants

          -  Those who are administered live vaccine parenterally within 120 days from being
             administered first investigative drug. (ex: measles vaccine, epidemic parotitis
             vaccine, rubella vaccine, cholera vaccine, chickenpox vaccine)

          -  Those who are administered interferon or antiviral agents within 120 days from being
             administered first investigative drug. (except for topical medication)

          -  Those who showed signs of an acute fever(over 38℃) within 72 hours from being
             administered first investigative drug.

          -  Those who showed signs of acute disease within 14 days from being administered first
             investigative drug.

          -  Those who donated whole blood within 60 days or ingredient blood within 30 days from
             being administered first investigative drug or those who are administered blood
             transfusion within 30 days from being administered first investigative drug.

          -  Those who took other investigative drugs within 60 days from being administered first
             investigative drug.

          -  Those who took herbal medicine within 30 days from being administered first
             investigative drug or took ethical drug(ETC) within 14 days or took over-the- counter
             drug(OTC) within 7 days from being administered first investigative drug.(but, Those
             who meet other conditions can join the clinical trials according to investigator's
             decision)

          -  Those who drink excessively caffeine-contained beverage, excessive alcohol, and who
             are smokers( caffeine&gt; 5 units/ day, alcohol&gt;21 units/ week, cigarette&gt; 10 pieces) or
             have a history of alcoholism

          -  Those who have a history of drug addiction, or showed positive response of urine-drug
             screening examination (ex: amphetamine, methamphetamine, barbiturate, cocaine, opiate,
             benzodiazepines, cannabinoid, methadone, etc)

          -  Those who showed positive sign of serum test(A-type hepatitis test(HAV IgM Ab), C-type
             hepatitis test(HCV Ab screening), HIV test(HIV Ag &amp; Ab), Syphilis high quality reagin
             test.

          -  Those whose serum creatinine, ALT, AST, or total bilirubin exceeded the standard 1.5
             times by the diagnostic lab test.

          -  Those who cannot eat standard meals provided by Seoul Asan medical center.

          -  Those who are judged disqualified to join clinical trials by investigator for other
             causes.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyun-Seop Bae, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of clinical pharmacology and therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of clinical pharmacology and therapeutics</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2012</study_first_submitted>
  <study_first_submitted_qc>May 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2012</study_first_posted>
  <last_update_submitted>January 1, 2014</last_update_submitted>
  <last_update_submitted_qc>January 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

